This study evaluated an integrated prognostic pipeline for breast cancer survival using TCGA-BRCA data. Clinical variables for 589 patients were converted into natural language sentences and encoded with BioBERT. Four molecular modalities from TCGA-BRCA were reduced via Sparse principal component analysis (Sparse PCA) to produce compact multi-omics feature sets. The dataset and code sources are publicly available as reported by the authors.
Clinical fields were transformed into sentence-like text and passed through a BioBERT encoder to produce dense clinical text representations. For molecular data, the authors applied Sparse PCA to four separate modalities to extract interpretable, low-dimensional components. These processing steps produced three sets of features for modeling: clinical-only (BioBERT encodings), multi-omics-only (Sparse PCA components), and integrated (clinical plus multi-omics components).
Three prediction algorithms were trained and compared: Cox proportional hazards regression, XGBoost adapted for survival outcomes, and random survival forest (RSF). Performance was evaluated relative to two simple references: a marginal Kaplan–Meier null model and a conventional age-and-stage Cox model. These baselines were included to contextualize gains from multi-modal integration.
The authors implemented a leakage-controlled evaluation using repeated stratified cross-validation. They generated pooled out-of-fold predictions to provide cross-validated performance estimates. The protocol emphasized preventing information leakage between training and test folds and producing stable estimates across repetitions. Statistical comparisons were performed across models and feature-set combinations.
The analytic cohort comprised 589 TCGA-BRCA patients with 88 observed deaths, corresponding to an event rate of 14.9%. Median follow-up time was 33.7 months. These cohort-level metrics frame the overall event count and follow-up duration underlying model performance and statistical power.
Across all experiments, the ordering of performance was consistently integrated > clinical-only > multi-omics-only for the nine feature-set by algorithm comparisons and across tested component settings. The best-performing model reported was the integrated feature set fit with random survival forest, which achieved Harrell's C = 0.685 (95% CI 0.620–0.754) and Uno's C = 0.748. By comparison, the conventional clinical Cox model attained Harrell's C = 0.637 (95% CI 0.559–0.707). These discrimination metrics indicate that integration yielded the highest measured concordance in this benchmark.
The integrated models significantly outperformed every multi-omics-only model, with reported P values in the range 0.008–0.044. However, when comparing the integrated pipeline to clinical-only models within the same evaluation framework, the observed difference in concordance (dC = 0.037) did not reach statistical significance (P = 0.128) at the available event count. The authors note that the inability to resolve a statistically significant gain over clinical features may reflect limited events rather than absence of any practical improvement.
The authors assessed calibration using Brier scores at landmark times. Brier scores for models approached the null (Kaplan–Meier) reference at 2 and 3 years, indicating limited improvement over the marginal survival estimate at those horizons. At 5 years, Brier scores improved modestly for the models, suggesting somewhat better probabilistic calibration or prediction at longer follow-up in this cohort.
Integration of BioBERT-derived clinical text representations with sparse multi-omics components produced the highest discrimination in this leakage-controlled, cross-validated benchmark for TCGA-BRCA survival prediction, with the integrated RSF model performing best. Although integration outperformed multi-omics-only approaches significantly, the incremental gain over clinical-only features was not statistically resolvable given the event count in this cohort. The authors recommend that multi-modal prognostic studies routinely report simple clinical baselines, null-model calibration, and cross-validated estimates to avoid overestimating performance and to ensure transparent benchmarking.
The authors declared no competing interests and affirmed that ethical approvals and participant consent procedures were followed and documented. Data sets used in the study are publicly available, with the authors referencing the xenabrowser platform as a source.